<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520971</url>
  </required_header>
  <id_info>
    <org_study_id>S64308</org_study_id>
    <nct_id>NCT04520971</nct_id>
  </id_info>
  <brief_title>Closed-loop Insulin Delivery in Pregnant Women With Type 1 Diabetes</brief_title>
  <acronym>CRISTAL</acronym>
  <official_title>Closed-loop Insulin Delivery in Pregnant Women With Type 1 Diabetes: a Randomized Controlled Trial: the CRISTAL Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imelda Hospital, Bonheiden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ Delta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onze Lieve Vrouw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital Groeninge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ Nikolaas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-centric open-label randomized controlled trial (RCT) with 11 Belgian centers and one&#xD;
      Dutch center in pregnant women with type 1 diabetes to assess safety, efficacy, feasibility&#xD;
      and cost-effectiveness of 780 MiniMed Medtronic hybrid closed-loop insulin system&#xD;
      (intervention group) compared to standard of care therapy (control group).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women will be recruited with a singleton pregnancy up to 12 weeks gestation. Participants&#xD;
      will be randomized 1/1 to 780 pump or standard of care (continue with current treatment of&#xD;
      insulin pump without closed-loop or multiple daily insulin injections). Participants will be&#xD;
      stratified according to study center, baseline Hba1c, and method of insulin delivery (pump or&#xD;
      injections). Participants will be followed-up till delivery. To account for differences in&#xD;
      the type of continuous glucose monitoring (CGM) used between the intervention group and the&#xD;
      control group, the same CGM system as in the 780 insulin pump group (Guardian™ Sensor 3 and&#xD;
      once available the Guardian 4 sensor) will be used in a blinded manner in the control group&#xD;
      to collect CGM data during at least four different time points in pregnancy: at 14-17 weeks,&#xD;
      20-23 weeks, 26-29 weeks and 33-36 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1/1 randomization to 780G or continue with standard of care</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time in range</measure>
    <time_frame>from 14 weeks to 36 weeks</time_frame>
    <description>time between 63-140mg/dl (pregnancy glycemic target range)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time in range during the night</measure>
    <time_frame>from 14 weeks to 36 weeks</time_frame>
    <description>time in range (63-140mg/dl) from midnight till 6am</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time below low day and night</measure>
    <time_frame>from 14 weeks to 36 weeks</time_frame>
    <description>time &lt;63mg/dl day and night</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overnight time low</measure>
    <time_frame>from 14 weeks to 36 weeks</time_frame>
    <description>time &lt;63mg/dl from midnight till 6am</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time in range during the day</measure>
    <time_frame>from 14 weeks to 36 weeks</time_frame>
    <description>time in range (63-140mg/dl) during the day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time in range early pregnancy</measure>
    <time_frame>from 9 weeks to 12 weeks</time_frame>
    <description>time in range (63-140mg/dl) 9-12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time in range during each trimester</measure>
    <time_frame>from 9 weeks to 36 weeks</time_frame>
    <description>time in range (63-140mg/dl) during each trimester</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c during each trimester</measure>
    <time_frame>from 9 weeks to 36 weeks</time_frame>
    <description>HbA1c (% and mmol/mol) during each trimester</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean glucose</measure>
    <time_frame>from 14 weeks to 36 weeks</time_frame>
    <description>mean glucose based on CGM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time above target (140mg/dl)</measure>
    <time_frame>from 14 weeks to 36 weeks</time_frame>
    <description>time &gt;140mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time above target (180mg/dl)</measure>
    <time_frame>from 14 weeks to 36 weeks</time_frame>
    <description>time &gt;180mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time below target (50mg/dl)</measure>
    <time_frame>from 14 weeks to 36 weeks</time_frame>
    <description>time &lt;50mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time below target (54mg/dl)</measure>
    <time_frame>from 14 weeks to 36 weeks</time_frame>
    <description>time &lt;54mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of hypoglycemia</measure>
    <time_frame>from 14 weeks to 36 weeks</time_frame>
    <description>low blood glucose index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time in nonpregnant target range</measure>
    <time_frame>from 14 weeks to 36 weeks</time_frame>
    <description>time 70-180mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM compliance</measure>
    <time_frame>from 14 weeks to 36 weeks</time_frame>
    <description>% of time use of CGM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin dose</measure>
    <time_frame>from 14 weeks to 36 weeks</time_frame>
    <description>total insulin dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycemic variability</measure>
    <time_frame>from 14 weeks to 36 weeks</time_frame>
    <description>standard deviation glucose values based on CGM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>variation glucose values</measure>
    <time_frame>from 14 weeks to 36 weeks</time_frame>
    <description>coefficient of variation based on CGM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAGE</measure>
    <time_frame>from 14 weeks to 36 weeks</time_frame>
    <description>mean amplitude of glucose variations based on CGM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nocturnal hypoglycemia</measure>
    <time_frame>from 9 weeks to 36 weeks</time_frame>
    <description>glucose &lt;50mg/dl from 23-07hour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severe hypoglycemia</measure>
    <time_frame>from 9 weeks to 36 weeks</time_frame>
    <description>hypoglycemia requiring third-part assistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of diabetic keto-acidosis</measure>
    <time_frame>from 9 weeks to 36 weeks</time_frame>
    <description>metabolic keto-acidosis with decreased ph and/or decreased bicarbonate in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gestational duration</measure>
    <time_frame>delivery</time_frame>
    <description>duration of pregnancy (weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration hospitalization delivery</measure>
    <time_frame>delivery</time_frame>
    <description>length of hospital stay (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of labor</measure>
    <time_frame>delivery</time_frame>
    <description>spontaneous, induced or cesarean section before labor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of delivery</measure>
    <time_frame>delivery</time_frame>
    <description>vaginal, forceps or vacuum, cesarean section during labor or planned cesarean section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of preterm delivery</measure>
    <time_frame>delivery</time_frame>
    <description>delivery &lt;37 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of gestational hypertension</measure>
    <time_frame>from 20 weeks to delivery</time_frame>
    <description>blood pressure of 140/90mmHg or higher starting after 20 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of worsening of chronic hypertension</measure>
    <time_frame>from 9 weeks to delivery</time_frame>
    <description>blood pressure of 140/90mmHg or higher start is present before 20 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of preeclampsia</measure>
    <time_frame>from 20 weeks to delivery</time_frame>
    <description>onset of new hypertension and proteinuria and/or end-organ dysfunction after 20 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of eclampsia</measure>
    <time_frame>from 20 weeks to delivery</time_frame>
    <description>generalized convulsions and/or coma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of HELLP syndrome</measure>
    <time_frame>from 20 weeks to delivery</time_frame>
    <description>hemolysis, elevated liver enzymes and a low platelet count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of IUGR</measure>
    <time_frame>from 20 weeks to delivery</time_frame>
    <description>intra-uterine growth restriction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of fetal malformation</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>congenital malformation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of miscarriage</measure>
    <time_frame>&lt;20 weeks</time_frame>
    <description>fetal loss &lt;20 weeks gestations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of termination of pregnancy</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>induced abortion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of stillbirth</measure>
    <time_frame>&gt;20 weeks</time_frame>
    <description>mors in utero &gt;20 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of neonatal death</measure>
    <time_frame>1 month after delivery</time_frame>
    <description>death &lt;1 months after delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sex of infant</measure>
    <time_frame>delivery</time_frame>
    <description>boy or girl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>birth weight</measure>
    <time_frame>delivery</time_frame>
    <description>birth weight (Kg and g)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of shoulder dystocia</measure>
    <time_frame>delivery</time_frame>
    <description>one or both of a baby's shoulders get stuck inside the mother's pelvis during labor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of birth trauma</measure>
    <time_frame>delivery</time_frame>
    <description>fracture, damage to nerves...</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of respiratory distress</measure>
    <time_frame>delivery</time_frame>
    <description>respiratory failure or distress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of hyperbilirubinaemia</measure>
    <time_frame>delivery</time_frame>
    <description>hyperbilirubinaemia with need of treatment with phototherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of macrosomia</measure>
    <time_frame>delivery</time_frame>
    <description>birth weight &gt;4Kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate with high birth weight</measure>
    <time_frame>delivery</time_frame>
    <description>birth weight &gt;4.5Kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of LGA infant (lage for gestational age)</measure>
    <time_frame>delivery</time_frame>
    <description>gestational age adjusted birth weight &gt;90th percentile according to the standardized Flemish birth charts adjusted for parity and sex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of SGA infant (small for gestational age)</measure>
    <time_frame>delivery</time_frame>
    <description>gestational age adjusted birth weight &lt;10th percentile according to the standardized Flemish birth charts adjusted for parity and sex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number with very large gestational age infants</measure>
    <time_frame>delivery</time_frame>
    <description>gestational age adjusted birth weight &gt;97th percentile according to the standardized Flemish birth charts adjusted for parity and sex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cord blood ph</measure>
    <time_frame>delivery</time_frame>
    <description>cord blood gas ph</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of neonatal hypoglycemia</measure>
    <time_frame>up to 5 days after delivery</time_frame>
    <description>neonatal hypoglycemia requiring intravenous dextrose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of NICU admission</measure>
    <time_frame>up to 30 days after delivery</time_frame>
    <description>Neonatal intensive care unit (NICU) admission defined as requiring a duration of at least 24 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration NICU admission</measure>
    <time_frame>up to 30 days after delivery</time_frame>
    <description>duration of NICU admission (days or weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of fetal hyperinsulinemia</measure>
    <time_frame>delivery</time_frame>
    <description>cord blood c-peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skinfolds newborn</measure>
    <time_frame>up to 3 days after delivery</time_frame>
    <description>sum of skinfolds (triceps, scapula and flank)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal fat mass</measure>
    <time_frame>up to 3 days after delivery</time_frame>
    <description>fat mass calculated by the formula of Catalano</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number with composite neonatal outcome</measure>
    <time_frame>delivery</time_frame>
    <description>pregnancy loss (miscarriage, still birth or neonatal death), LGA, respiratory distress syndrome, birth trauma, shoulder dystocia, neonatal hypoglycemia and NICU admission</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Type1 Diabetes</condition>
  <arm_group>
    <arm_group_label>780G closed-loop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>780 closed-loop insulin delivery system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard of care treatment (continue with current treatment of insulin pump without closed-loop or multiple daily insulin injections).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>780G</intervention_name>
    <description>780G closed-loop insulin delivery system (Medtronic)</description>
    <arm_group_label>780G closed-loop</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>standard of care</intervention_name>
    <description>continue with standard of care treatment (pump without closed-loop or MDI)</description>
    <arm_group_label>standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with type 1 diabetes (T1DM), diagnosed with T1DM at least 1 year before&#xD;
             pregnancy&#xD;
&#xD;
          -  Age 18-45 years&#xD;
&#xD;
          -  A singleton pregnancy confirmed by b-HCG in blood and/or ultrasound-confirmed&#xD;
             gestational age up to 11 weeks and 6 days.&#xD;
&#xD;
          -  Treated with intensive insulin treatment (either MDI or insulin pump). A closed-loop&#xD;
             system can only be used in manual mode.&#xD;
&#xD;
          -  Have a booking HbA1c (measurement taken at the first antenatal clinic visit after&#xD;
             confirmed pregnancy) level ≤10%.&#xD;
&#xD;
          -  Participants need to speak and understand Flemish, French or English and have e-mail&#xD;
             access.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The use of a closed-loop insulin delivery system in auto mode.&#xD;
&#xD;
          -  A twin (multiple) pregnancy&#xD;
&#xD;
          -  A physical or psychological disease likely to interfere with the conduct of the study&#xD;
             (based on the evaluation by the treating physician)&#xD;
&#xD;
          -  Medications known to interfere with glucose metabolism&#xD;
&#xD;
          -  An insulin dose of ≥1.5 units/kg&#xD;
&#xD;
          -  Known allergy to adhesives due to infusion set and/or CGM&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katrien Benhalima, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katrien Benhalima, MD PhD</last_name>
    <phone>003216340614</phone>
    <email>katrien.benhalima@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaat Beunen, master</last_name>
    <email>kaat.beunen@student.kuleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OLV Aalst-Asse</name>
      <address>
        <city>Aalst</city>
        <state>Oost-Vlaanderen</state>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Nobels, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imelda Bonheiden</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Da Hae Lee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ St Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youri Taes, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLouvain</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vanessa Preumont, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Van Wilder, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joke Marlier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge Kortrijk</name>
      <address>
        <city>Kortrijk</city>
        <zip>8510</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerd Vanhaverbeke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrien Benhalima, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Roeselare</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Aers, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Ballaux, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joke Cuypers, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Siegelaar, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>closed-loop insulin delivery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

